Intelligence · Clinical pipeline
Metabolic & obesity · Approved programs
Metabolic & obesity programs at Approved programs — ClinicalTrials.gov pipeline intelligence.
Programs 11
Quick answer
Metabolic & obesity Approved programs programs: NovaPharmaNews indexes 11 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.
Top sponsors
- Takeda 21 programs
- First People's Hospital 15 programs
- Disc Medicine 7 programs
- Regeneron UK 7 programs
- George Institute for 5 programs
- Chinese Academy of 4 programs
- Hospital Authority 4 programs
- Sanofi Pasteur MSD 4 programs
- ANI PHARMACEUTICALS 3 programs
- Eli Lilly and 3 programs
- HALOZYME THERAPEUTICS 3 programs
- NovoThirteen 3 programs
Pipeline programs
-
ANGELO
The George Institute
Obesity
1 trial -
Berberine plus lifestyle intervention
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Obesity
1 trial -
Candesartan and Hydrochlorothiazide
Takeda
Obesity
1 trial -
ESOMEPRAZOLE, ESOMEPRAZOLE
Fondazione Telethon ETS
obesity
1 trial -
EXPAREL
Pacira Ireland Limited
Obesity
1 trial -
Intravenous Ibuprofen
CUMBERLAND PHARMACEUTICALS INC
Obesity
1 trial -
NN9536-7752
NovoThirteen
Obesity
1 trial -
Pioglitazone
Takeda
Obesity
1 trial -
Semaglutide
United Therapeutics Europe Ltd
Obesity
1 trial -
Semaglutide B 3.0 mg/ml PDS290
Disc Medicine
obesity
1 trial -
Simvastatin
Hospital Authority, Hong Kong
Obesity
1 trial
Frequently asked questions
How many metabolic & obesity Approved programs programs exist?
11 programs match both the therapeutic area and stage filters in our published index.